A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Thomas Starkey; Maria C. Ionescu; Michael Tilby; Martin Little; Emma Burke; Matthew W. Fittall; Sam Khan; Justin K. H. Liu; James R. Platt; Rosie Mew; Arvind R. Tripathy; Isabella Watts; Sophie Therese Williams; Nathan Appanna; Youssra Al-Hajji; Matthew Barnard; Liza Benny; Alexander Burnett; Jola Bytyci; Emma L. Cattell; Vinton Cheng; James J. Clark; Leonie Eastlake; Kate Gerrand; Qamar Ghafoor; Simon Grumett; Catherine Harper-Wynne; Rachel Kahn; Alvin J. X. Lee; Oliver Lomas; Anna Lydon; Hayley Mckenzie; Hari Panneerselvam; Jennifer S. Pascoe; Grisma Patel; Vijay Patel; Vanessa A. Potter; Amelia Randle; Anne S. Rigg; Tim M. Robinson; Rebecca Roylance; Tom W. Roques; Stefan Rozmanowski; René L. Roux; Ketan Shah; Remarez Sheehan; Martin Sintler; Sanskriti Swarup; Harriet Taylor; Tania Tillett; Mark Tuthill; Sarah Williams; Yuxin Ying; Andrew Beggs; Tim Iveson; Siow Ming Lee; Gary Middleton; Mark Middleton; Andrew Protheroe; Tom Fowler; Peter Johnson; Lennard Y. W. Lee

doi:10.1038/s41598-023-36990-9

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, Arvind R. Tripathy, Isabella Watts, Sophie Therese Williams, Nathan Appanna, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Jola Bytyci, Emma L. CattellVinton Cheng, James J. Clark, Leonie Eastlake, Kate Gerrand, Qamar Ghafoor, Simon Grumett, Catherine Harper-Wynne, Rachel Kahn, Alvin J. X. Lee, Oliver Lomas, Anna Lydon, Hayley Mckenzie, Hari Panneerselvam, Jennifer S. Pascoe, Grisma Patel, Vijay Patel, Vanessa A. Potter, Amelia Randle, Anne S. Rigg, Tim M. Robinson, Rebecca Roylance, Tom W. Roques, Stefan Rozmanowski, René L. Roux, Ketan Shah, Remarez Sheehan, Martin Sintler, Sanskriti Swarup, Harriet Taylor, Tania Tillett, Mark Tuthill, Sarah Williams, Yuxin Ying, Andrew Beggs, Tim Iveson, Siow Ming Lee, Gary Middleton, Mark Middleton, Andrew Protheroe, Tom Fowler, Peter Johnson, Lennard Y. W. Lee^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

43 Downloads (Pure)

Abstract

Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

Original language	English
Article number	11327
Number of pages	8
Journal	Scientific Reports
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41598-023-36990-9
Publication status	Published - 25 Jul 2023

Bibliographical note

Keywords

Humans
COVID-19/epidemiology
SARS-CoV-2
England/epidemiology
Neoplasms/epidemiology
Phenotype
Case-Control Studies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-023-36990-9Licence: Creative Commons: Attribution (CC BY)

StarkeyT2023PopulationFinal published version, 981 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

Starkey, T., Ionescu, M. C., Tilby, M., Little, M., Burke, E., Fittall, M. W., Khan, S., Liu, J. K. H., Platt, J. R., Mew, R., Tripathy, A. R., Watts, I., Williams, S. T., Appanna, N., Al-Hajji, Y., Barnard, M., Benny, L., Burnett, A., Bytyci, J., ... Lee, L. Y. W. (2023). A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP). Scientific Reports, 13(1), Article 11327. https://doi.org/10.1038/s41598-023-36990-9

@article{95d6ebfa7f024a03bcab948d8ae00b5c,

title = "A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)",

abstract = "Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.",

keywords = "Humans, COVID-19/epidemiology, SARS-CoV-2, England/epidemiology, Neoplasms/epidemiology, Phenotype, Case-Control Studies",

author = "Thomas Starkey and Ionescu, {Maria C.} and Michael Tilby and Martin Little and Emma Burke and Fittall, {Matthew W.} and Sam Khan and Liu, {Justin K. H.} and Platt, {James R.} and Rosie Mew and Tripathy, {Arvind R.} and Isabella Watts and Williams, {Sophie Therese} and Nathan Appanna and Youssra Al-Hajji and Matthew Barnard and Liza Benny and Alexander Burnett and Jola Bytyci and Cattell, {Emma L.} and Vinton Cheng and Clark, {James J.} and Leonie Eastlake and Kate Gerrand and Qamar Ghafoor and Simon Grumett and Catherine Harper-Wynne and Rachel Kahn and Lee, {Alvin J. X.} and Oliver Lomas and Anna Lydon and Hayley Mckenzie and Hari Panneerselvam and Pascoe, {Jennifer S.} and Grisma Patel and Vijay Patel and Potter, {Vanessa A.} and Amelia Randle and Rigg, {Anne S.} and Robinson, {Tim M.} and Rebecca Roylance and Roques, {Tom W.} and Stefan Rozmanowski and Roux, {Ren{\'e} L.} and Ketan Shah and Remarez Sheehan and Martin Sintler and Sanskriti Swarup and Harriet Taylor and Tania Tillett and Mark Tuthill and Sarah Williams and Yuxin Ying and Andrew Beggs and Tim Iveson and Lee, {Siow Ming} and Gary Middleton and Mark Middleton and Andrew Protheroe and Tom Fowler and Peter Johnson and Lee, {Lennard Y. W.}",

note = "{\textcopyright} 2023. The Author(s).",

year = "2023",

month = jul,

day = "25",

doi = "10.1038/s41598-023-36990-9",

language = "English",

volume = "13",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Starkey, T, Ionescu, MC, Tilby, M, Little, M, Burke, E, Fittall, MW, Khan, S, Liu, JKH, Platt, JR, Mew, R, Tripathy, AR, Watts, I, Williams, ST, Appanna, N, Al-Hajji, Y, Barnard, M, Benny, L, Burnett, A, Bytyci, J, Cattell, EL, Cheng, V, Clark, JJ, Eastlake, L, Gerrand, K, Ghafoor, Q, Grumett, S, Harper-Wynne, C, Kahn, R, Lee, AJX, Lomas, O, Lydon, A, Mckenzie, H, Panneerselvam, H, Pascoe, JS, Patel, G, Patel, V, Potter, VA, Randle, A, Rigg, AS, Robinson, TM, Roylance, R, Roques, TW, Rozmanowski, S, Roux, RL, Shah, K, Sheehan, R, Sintler, M, Swarup, S, Taylor, H, Tillett, T, Tuthill, M, Williams, S, Ying, Y, Beggs, A, Iveson, T, Lee, SM, Middleton, G, Middleton, M, Protheroe, A, Fowler, T, Johnson, P & Lee, LYW 2023, 'A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)', Scientific Reports, vol. 13, no. 1, 11327. https://doi.org/10.1038/s41598-023-36990-9

TY - JOUR

T1 - A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

AU - Starkey, Thomas

AU - Ionescu, Maria C.

AU - Tilby, Michael

AU - Little, Martin

AU - Burke, Emma

AU - Fittall, Matthew W.

AU - Khan, Sam

AU - Liu, Justin K. H.

AU - Platt, James R.

AU - Mew, Rosie

AU - Tripathy, Arvind R.

AU - Watts, Isabella

AU - Williams, Sophie Therese

AU - Appanna, Nathan

AU - Al-Hajji, Youssra

AU - Barnard, Matthew

AU - Benny, Liza

AU - Burnett, Alexander

AU - Bytyci, Jola

AU - Cattell, Emma L.

AU - Cheng, Vinton

AU - Clark, James J.

AU - Eastlake, Leonie

AU - Gerrand, Kate

AU - Ghafoor, Qamar

AU - Grumett, Simon

AU - Harper-Wynne, Catherine

AU - Kahn, Rachel

AU - Lee, Alvin J. X.

AU - Lomas, Oliver

AU - Lydon, Anna

AU - Mckenzie, Hayley

AU - Panneerselvam, Hari

AU - Pascoe, Jennifer S.

AU - Patel, Grisma

AU - Patel, Vijay

AU - Potter, Vanessa A.

AU - Randle, Amelia

AU - Rigg, Anne S.

AU - Robinson, Tim M.

AU - Roylance, Rebecca

AU - Roques, Tom W.

AU - Rozmanowski, Stefan

AU - Roux, René L.

AU - Shah, Ketan

AU - Sheehan, Remarez

AU - Sintler, Martin

AU - Swarup, Sanskriti

AU - Taylor, Harriet

AU - Tillett, Tania

AU - Tuthill, Mark

AU - Williams, Sarah

AU - Ying, Yuxin

AU - Beggs, Andrew

AU - Iveson, Tim

AU - Lee, Siow Ming

AU - Middleton, Gary

AU - Middleton, Mark

AU - Protheroe, Andrew

AU - Fowler, Tom

AU - Johnson, Peter

AU - Lee, Lennard Y. W.

PY - 2023/7/25

Y1 - 2023/7/25

N2 - Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

AB - Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

KW - Humans

KW - COVID-19/epidemiology

KW - SARS-CoV-2

KW - England/epidemiology

KW - Neoplasms/epidemiology

KW - Phenotype

KW - Case-Control Studies

U2 - 10.1038/s41598-023-36990-9

DO - 10.1038/s41598-023-36990-9

M3 - Article

C2 - 37491478

SN - 2045-2322

VL - 13

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 11327

ER -

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this